Form 10-Q · Quarterly report
Agilent Technologies 10-Q, filed Sep 1, 2026
- Filed
- CIK
- 0001090872
- Accession no.
- 0001090872-26-000064
Summary
Agilent Technologies reported net revenue of $1,878 million for its fiscal third quarter ended July 31, 2026, up 8% from a year earlier, and net income of $362 million, after closing its $950 million acquisition of Biocare in June and issuing $600 million in 4.90% senior notes due 2032. Management said customer capital budget availability has largely normalized and that tariff and Middle East conflict impacts on costs were mitigated through supply chain, pricing, and cost-efficiency measures.
Key points
- Agilent Technologies acquired Biocare, the parent of its pathology business, for $950 million in net consideration on June 24, 2026, making it a wholly owned subsidiary within the Life Sciences and Diagnostics Markets segment.
- Agilent issued $600 million of 4.90% senior notes maturing January 15, 2032, sold at 99.968% of principal.
- Net revenue was $1,878 million for the quarter ended July 31, 2026, up 8% year over year, with net income of $362 million versus $336 million a year earlier.
- The U.S. Supreme Court invalidated certain IEEPA tariffs in February 2026 and the Court of International Trade ordered refunds subject to appeal; Agilent has filed refund claims but says timing and approval are uncertain.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
ITEM 2. MANAGEMENT’S DISCUSSION Executive Summary Agilent Technologies, Inc. ("we," "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Acquisition of Biocare. On June 24, 2026, we acquired 100 percent of the outstanding capital stock of BC Midco I, Inc. (“Biocare”) for a net consideration paid of $950 million. Biocare is a leading provider of clinical and research solutions and is included within our Life Sciences and Diagnostics Markets segment. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.